Treatment of POEMS syndrome with lenalidomide and dexamethasone

DOI Web Site PubMed
  • GOTO Akari
    Department of Hematology, Sapporo Medical University School of Medicine
  • IYAMA Satoshi
    Department of Hematology, Sapporo Medical University School of Medicine
  • SUGAMA Yusuke
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • YOSHIDA Masahiro
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • IBATA Soshi
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • TATEKOSHI Ayumi
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • FUJITA Chisa
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • KIKUCHI Shohei
    Department of Hematology, Sapporo Medical University School of Medicine Department of Medical Oncology, Sapporo Medical University School of Medicine
  • IKEDA Hiroshi
    Department of Hematology, Sapporo Medical University School of Medicine
  • MURASE Kazuyuki
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • TAKADA Kohichi
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • KATO Junji
    Department of Medical Oncology, Sapporo Medical University School of Medicine
  • KOBUNE Masayoshi
    Department of Hematology, Sapporo Medical University School of Medicine

Bibliographic Information

Other Title
  • レナリドミド・デキサメタゾン療法を施行したPOEMS症候群
  • 症例報告 第53回日本血液学会春季北海道地方会 会長推薦演題 レナリドミド・デキサメタゾン療法を施行したPOEMS症候群
  • ショウレイ ホウコク ダイ53カイ ニホン ケツエキ ガッカイ シュンキ ホッカイドウ チホウカイ カイチョウ スイセン エンダイ レナリドミド ・ デキサメタゾン リョウホウ オ シコウ シタ POEMS ショウコウグン

Search this article

Abstract

<p>We report three cases of POEMS syndrome treated with lenalidomide and dexamethasone who presented with peripheral neuropathy. All of them had markedly elevated serum vascular endothelial growth factor (VEGF) levels treated with lenalidomide and dexamethasone for severe peripheral neuropathy, which normalized serum VEGF levels and improved peripheral neuropathy. The standard treatment of POEMS syndrome has not been established, but has been effectively treated with high-dose chemotherapy with autologous stem cell transplantation. Newer agents currently used for plasma cell dyscrasias include bortezomib and immunomodulatory drugs, such as thalidomide and lenalidomide. A randomized controlled trial on thalidomide plus dexamethasone for POEMS syndrome showed reduced serum VEGF levels after therapy; however, the incidence of peripheral neuropathy, a well-known side effect of both thalidomide and bortezomib, increased. Lenalidomide is associated with lower incidence of peripheral neuropathy compared to thalidomide and bortezomib, making it a reasonable treatment option for POEMS syndrome.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 60 (4), 308-313, 2019

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top